Skip to main content
Smart Investors Daily
CytomX Therapeutics, Inc. logo

NASDAQ · CTMX

CytomX Therapeutics, Inc.

Healthcare · Biotechnology

$1.99

Down-$0.06 (-2.70%)

Updated Nov 17, 2026, 5:34 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
686.8M
P/E ratio
23.88
Dividend yield
0.00%
52-week range
$1.90 – $8.21
Volume
2.6M
Avg. volume
3.54M

Price performance · CTMX

CTMX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

CTMX closed at $1.99 after 21 trading sessions, down 15.17% for the selected period.

Last close
$1.99
Period change
-15.17%
Period low
$1.98
Period high
$2.51
Daily close
View OHLC price history
CTMX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$2.02$2.08$1.94$1.9852.6M
Nov 13, 2026$2.02$2.1252$1.96$2.042.72M
Nov 12, 2026$2.15$2.18$2.03$2.043.16M
Nov 11, 2026$1.99$2.17$1.96$2.134.99M
Nov 10, 2026$1.99$2.02$1.90$1.9816.65M
Nov 9, 2026$2.24$2.28$1.95$1.9812.91M
Nov 6, 2026$2.24$2.27$2.1201$2.192.73M
Nov 5, 2026$2.35$2.35$2.11$2.143.86M
Nov 4, 2026$2.26$2.36$2.175$2.356.59M
Nov 3, 2026$2.24$2.32$2.155$2.183.41M
Nov 2, 2026$2.36$2.39$2.14$2.239.47M
Oct 30, 2026$2.28$2.36$2.21$2.344.94M
Oct 29, 2026$2.38$2.42$2.25$2.294.63M
Oct 28, 2026$2.28$2.385$2.25$2.364.08M
Oct 27, 2026$2.21$2.36$2.16$2.313.73M
Oct 26, 2026$2.31$2.33$2.18$2.2255.22M
Oct 23, 2026$2.41$2.42$2.305$2.324.37M
Oct 22, 2026$2.38$2.47$2.37$2.442.44M
Oct 21, 2026$2.525$2.61$2.39$2.403.11M
Oct 20, 2026$2.36$2.55$2.34$2.514.1M
Oct 19, 2026$2.31$2.35$2.24$2.342.05M

Latest CTMX news

The latest Smart Investors Daily articles mentioning CTMX.

CTMX research

Overview

Company profile and research snapshot.

Company profile

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$6.50
Implied upside
—
Analysts
14
CTMX recent ratings
DateFirmRatingTarget
Nov 12, 2026JP MorganOverweight—
Nov 6, 2026WedbushOutperform—
Aug 13, 2026JP MorganOverweight—
Aug 10, 2026GuggenheimBuy—
May 11, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

CytomX Therapeutics Q3 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027. The update is expected to include the first look at overall survival data

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.